# US 2023/0058618 A1 · Esketamine formulations and methods for preparation and storage

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058618 A1
- Document ID: US20230058618A1
- Status: Published application
- Kind: A1
- Application number: 17/783,744
- Filed: 2020-12-14
- Published: 2023-02-23
- Earliest claimed: 2019-12-12
- Assignees: Janssen Pharmaceutica NV
- Applicants: Janssen Pharmaceutica NV
- Inventors: Caroline Anne AERTS; Kris KAYENS; Koen Maria SCHRIJNEMAKERS; Mohamedilias JIMIDAR
- Web page: https://patentgrep.com/patent/US20230058618A1

## CPC

- A61J 1/065: {Rigid ampoules, e.g. glass ampoules}
- A61K 9/0043: {Nose}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The disclosure is directed to pharmaceutical compositions comprising esketamine or a pharmaceutically acceptable salt thereof and an oxidative degradant. In certain aspects, the oxidative degradant is 6-(2-chlorophenyl)-6-oxohexanoic acid or a pharmaceutically acceptable salt thereof. Methods for limiting the formation of oxidative degradants in a pharmaceutical composition comprising esketamine or a pharmaceutically acceptable salt thereof are also disclosed.

## Claims

### Claim 1

A pharmaceutical composition comprising esketamine or a pharmaceutically acceptable salt thereof and an oxidative degradant.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the oxidative degradant is 6-(2-chlorophenyl)-6-oxohexanoic acid or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, comprising (i) not more than 0.2% (HPLC area) of 6-(2-chlorophenyl)-6-oxohexanoic acid or a pharmaceutically acceptable salt thereof, relative to the amount of the esketamine, or (ii) not more than 0.2 w/w of 6-(2-chlorophenyl)-6-oxohexanoic acid or a pharmaceutically acceptable salt thereof, relative to the weight of the esketamine.

### Claim 4 (depends on 2)

The pharmaceutical composition of claim 2, comprising (i) not more than 0.2% (HPLC area) of 6-(2-chlorophenyl)-6-oxohexanoic acid or a pharmaceutically acceptable salt thereof, relative to the amount of esketamine or (ii) not more than 0.2 w/w of 6-(2-chlorophenyl)-6-oxohexanoic acid or a pharmaceutically acceptable salt thereof, relative to the weight of the esketamine, after storage for at least 6 months, for at least 12 months, for at least 18 months, or for at least 24 months, optionally wherein the storage occurs in the absence of light.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, comprising not more than 0.1% (HPLC area) or not more than 0.1% w/w of 6-(2-chlorophenyl)-6-oxohexanoic acid or a pharmaceutically acceptable salt thereof, relative to the amount of esketamine, after storage for at least 6 months, for at least 12 months, for at least 18 months, or for at least 24 months, optionally wherein the storage occurs in the absence of light.

### Claim 6 (depends on 2)

The pharmaceutical composition of claim 2, comprising not more than about 120 ppm of 6-(2-chlorophenyl)-6-oxohexanoic acid or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 2)

The pharmaceutical composition of claim 2, comprising not more than about 120 ppm of 6-(2-chlorophenyl)-6-oxohexanoic acid or a pharmaceutically acceptable salt thereof after storage for at least 6 months, for at least 12 months, for at least 18 months, or for at least 24 months, optionally wherein the storage occurs in the absence of light.

### Claim 8 (depends on 4)

The pharmaceutical composition of claim 4, wherein the storage is at a temperature in the range of about 20° C. to about 75° C.

### Claim 9 (depends on 4)

The pharmaceutical composition of claim 4, wherein the storage is in an atmosphere having a relative humidity of about 25% to about 80%.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in a closed container, preferably wherein the closed container is a sealed glass vial.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein the closed container is substantially opaque to light, preferably wherein the closed container has an opacity permitting about 10% or less of light from passing through the container, as measured using an opacimeter.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10, wherein the closed container is within a second container that is substantially opaque to light, preferably wherein the second container has an opacity permitting about 10% or less of light from passing through the container, as measured using an opacimeter.

### Claim 13 (depends on 2)

The pharmaceutical composition of claim 2, comprising not more than 0.2% (HPLC area) or not more than 0.2% w/w of 6-(2-chlorophenyl)-6-oxohexanoic acid or a pharmaceutically acceptable salt thereof, relative to the amount/weight of esketamine respectively, after storage for 6 months at a temperature in the range of about 20° C. to about 75° C., in an atmosphere having a relative humidity of about 25% to about 80%, and in a closed container having an opacity permitting about 10% or less of light from passing through the container, as measured using an opacimeter.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, comprising not more than 0.2% (HPLC area) or not more than 0.2% w/w of 6-(2-chlorophenyl)-6-oxohexanoic acid or a pharmaceutically acceptable salt thereof, relative to the amount/weight of esketamine respectively, after storage under said conditions for 12 months, 18 months or 24 months.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, that is an intranasal pharmaceutical composition.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, further comprising one or more of citric acid monohydrate, edetate disodium, sodium hydroxide, and water.

### Claim 17

A method for preventing the formation of oxidative degradants in a pharmaceutical composition comprising esketamine or a pharmaceutically acceptable salt thereof, comprising one or more of:
(a) preparing the pharmaceutical composition in the absence of light;
(b) storing the pharmaceutical composition in the absence of light;
(c) exposing the pharmaceutical composition to about 6 hours or less of light; or
(d) filling a container with the pharmaceutical composition in the absence of light.

### Claim 18 (depends on 17)

The method of claim 17, comprising exposing the pharmaceutical composition to 6 hours or less of light during the preparation of the composition and the filling of a container with the composition; and then storing the pharmaceutical composition in a container having an opacity permitting about 10% or less of light from passing through the container, as measured using an opacimeter.

### Claim 19 (depends on 18)

The method of claim 18, comprising exposing the pharmaceutical composition to 1 hour or less of light, preferably 30 minutes or less of light, during the preparation of the composition and the filling of a container with the composition.

### Claim 20 (depends on 17)

The method of claim 17, comprising selecting a container for storing the pharmaceutical composition that has an opacity permitting about 10% or less of light from passing through the container, as measured using an opacimeter.

### Claim 21 (depends on 17)

The method of claim 17, comprising:
a) exposing the pharmaceutical composition to 6 hours or less of light during preparation of the composition;
b) selecting a container that has an opacity permitting about 10% or less of light from passing through the container, as measured using an opacimeter; and
c) filling said container with the pharmaceutical composition, preferably in the absence of light.

### Claim 22 (depends on 21)

The method of claim 21, further comprising storing the pharmaceutical composition in said container in the absence of light.

### Claim 23

A process for preparing a pharmaceutical composition comprising esketamine or a pharmaceutically acceptable salt thereof and not more than 0.2% (HPLC area) or not more than 0.2% w/w of 6-(2-chlorophenyl)-6-oxohexanoic acid or a pharmaceutically acceptable salt thereof, relative to the amount/weight of esketamine respectively, comprising mixing the esketamine or a pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipients; and exposing the esketamine to about 6 hours or less of light.

### Claim 24

A process for preparing a pharmaceutical composition comprising esketamine or a pharmaceutically acceptable salt thereof and not more than about 120 ppm of 6-(2-chlorophenyl)-6-oxohexanoic acid or a pharmaceutically acceptable salt thereof, comprising mixing the esketamine or a pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipients; and exposing the esketamine to about 6 hours or less of light.

### Claim 25 (depends on 23)

The process of claim 23, wherein the mixing is performed using a mixing substrate that is substantially opaque to light, preferably wherein the mixing substrate has an opacity permitting about 10% or less of light from passing through the container, as measured using an opacimeter.

### Claim 26 (depends on 25)

The process of claim 25, wherein the mixing substrate comprises a light protective foil.

### Claim 27 (depends on 23)

The process of claim 23, further comprising filling a container with the pharmaceutical composition.

### Claim 28 (depends on 27)

The process of claim 27, wherein the filling is performed using a filling substrate that is substantially opaque to light, preferably wherein the filling substrate has an opacity permitting about 10% or less of light from passing through the container, as measured using an opacimeter.

### Claim 29 (depends on 28)

The process of claim 28, wherein the filling substrate comprises a black silicon sheet or stainless steel.

### Claim 30 (depends on 28)

The process of claim 28, further comprising covering the container with a second container that is substantially opaque to light, preferably wherein the second container is an aluminum bag.
